Dose-escalation, Open-label, Non-randomized Phase I Study to Evaluate the Safety and Immunogenicity of Three Concentrations of a rNDV Vaccine Against SARS-CoV-2 Administered by the Intranasal and Intramuscular Route to Healthy Volunteers
Latest Information Update: 27 Jul 2023
At a glance
- Drugs COVID-19 vaccine-Castlevax (Primary) ; COVID-19 vaccine-Castlevax (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Avimex
- 08 Dec 2022 Status changed from active, no longer recruiting to completed.
- 24 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 26 May 2021 Status changed from not yet recruiting to recruiting.